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To test the feasibility of using the survivin promoter to induce specific expression of sodium/iodide symporter (NIS) in cancer cell
lines and tumors for targeted use of radionuclide therapy, a recombinant adenovirus, Ad-SUR-NIS, that expressed the NIS gene
under control of the survivin promoter was constructed. Ad-SUR-NIS mediating iodide uptake and cytotoxicity was performed in
vitro. Scintigraphic, biodistribution and radioiodine therapy studies were performed in vivo. PC-3 (prostate); HepG2 (hepatoma)
and A375 (melanoma) cancer cells all exhibited perchlorate-sensitive iodide uptake after infection with Ad-SUR-NIS, B50 times
higher than that of negative control Ad-CMV-GFP-infected cells. No significant iodide uptake was observed in normal human
dental pulp fibroblast (DPF) cells after infection with Ad-SUR-NIS. Clonogenic assays demonstrated that Ad-SUR-NIS-infected
cancer cells were selectively killed by exposure to
131I. Ad-SUR-NIS-infected tumors show significant radioiodine accumulation
(13.3±2.85% ID per g at 2h post-injection), and the effective half-life was 3.1h. Moreover, infection with Ad-SUR-NIS in
combination with
131I suppressed tumor growth. These results indicate that expression of NIS under control of the survivin promoter
can likely be used to achieve cancer-specific expression of NIS in many types of cancers. In combination with radioiodine therapy,
this strategy is a possible method of cancer gene therapy.
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Introduction
The sodium/iodide symporter (NIS), an intrinsic mem-
brane glycoprotein with 13 putative transmembrane
domains, has an important role in the biosynthesis of
thyroid hormones by mediating the active transport of
iodide into thyrocytes.
1–3 NIS is critical for the diagnosis
and therapeutic management of thyroid diseases, includ-
ing thyroid carcinoma. Cloning of the rat and human
NIS genes in 1996 and extensive characterization of these
genes have paved the way to novel radionuclide gene
therapy strategies.
1,4 Through targeted transfer and
expression of the NIS gene, radioiodine treatment could
be used to treat non-thyroid malignant disease in addition
to thyroid carcinoma.
Tumor-specific expression of the NIS gene has been
performed with promising results in a variety of tumors,
including prostate carcinoma,
5–9 hepatocellular carci-
noma,
9–12 medullary thyroid carcinoma,
13 colon cancer,
14
breast cancer
15 and neuroendocrine tumors.
16 For exam-
ple, prostate tumors were successfully treated in vivo with
systemic administration of
131I,
188Re and
211At following
selective expression of NIS under control of the prostate
specific antigen promoter. Although previous studies have
been promising, the use of such tissue-specific promoters
has a limited scope. Therefore, the identification of a
more general tumor-specific promoter to regulate NIS
expression could be useful for expanding this strategy for
treatment of a wide variety of tumors.
Survivin, a member of the inhibitor of apoptosis gene
family, is usually expressed in the embryonic lung and
fetal organs in the developmental stages but undetectable
in normal adult tissues other than the thymus, placenta,
CD34þ stem cells and basal colonic epithelial cells.
17–21
However, survivin seems to be selectively expressed in
transformed cells and in most human cancers, including
lung, breast, pancreatic and colon carcinomas, soft tissue
sarcomas, brain tumors, melanoma, neuroblastoma
and hematologic malignancies.
22 Clinical studies have
indicated a positive correlation between high survivin
Received 7 February 2010; revised 22 June 2010; accepted 2
September 2010; published online 29 October 2010
Correspondence: Professor A Kuang, Department of Nuclear
Medicine, National Key Discipline of Medical Imaging and
Nuclear Medicine, West China Hospital, Sichuan University,
Chengdu 610041, China.
E-mail: kuanganren@263.net
4These two authors contributed equally to this work.
Cancer Gene Therapy (2011) 18, 144–152
r 2011 Nature America, Inc. All rights reserved 0929-1903/11
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cancer patients.
23 Previous studies have identified a
putative region of the survivin promoter that is likely
responsible for the induction of specific, high-level
expression in tumors.
24,25 The survivin promoter contains
multiple cell cycle-dependent elements and a cell cycle
gene homology region. This region has been suggested to
control expression of various G2-M-regulated genes,
including the survivin gene, in a manner correlating with
G2-M cell cycle periodicity.
24
In this study, we have developed a tumor-targeting
adenovirus that expresses the NIS gene under control
of the survivin promoter. We investigated the utility of
this system for molecular imaging and radioiodine gene
therapy. The results reported herein demonstrate the
potential efficacy and selectivity of a combination of
radioiodine therapy and adenovirus-mediated expression
of the NIS gene under the control of the survivin
promoter for cancer therapy.
Materials and methods
Cell lines
The human prostate cancer cell line, PC-3; the human
hepatocellular carcinoma cell line, HepG2; the human
melanoma cell line, A375 and the adenoviral transformed
human embryonic kidney cell line, 293, were purchased
from the American Type Culture Collection (ATCC,
Rockville, MD). All cancer cell lines were cultured in
RPMI 1640 medium supplemented with 10% calf serum
(Gibco, Carlsbad, CA), 2mM glutamine, 100IUml
–1
penicillin and 100ngml
–1 streptomycin. Cells were main-
tained at 371C in a humidified atmosphere containing 5%
CO2. Both 293 cells and a control human dental pulp
fibroblast cell line (DPF; a kind gift from Dr Peng Li,
West China College of Stomatology, Sichuan University)
were cultured in Dulbecco’s Modified Eagle Medium
(high glucose) medium supplemented with 10% FBS and
100IUml
–1 penicillin/streptomycin (100ngml
–1).
Construction of plasmids and recombinant adenovirus
In order to generate the luciferase expression plasmid
under the control of the survivin promoter (pSUR-LUC),
an B260bp fragment of the human survivin gene
promoter (B222 to þ39, GeneBank Accession Number
AY795969) was amplified from PC-3 genomic DNA by
PCR. This region contains two cell cycle-dependent
elements and one cell cycle gene homology region. The
sequences of the oligonucleotide primers were as follows:
forward primer, 50-AGATCTGCACGCGTTCTTTGAA
AGC-30, and reverse primer, 50-AAGCTTCCACCTCTG
CCAACGGGTC-3, which allowed for the introduction
of BglII and HindIII sites (underlined in the respective
sequences). The survivin promoter was T/A cloned into
the PMD-T18 vector for sequencing, and then subcloned
using the BglII and HindIII sites into the luciferase
vector pGL3-basic (Promega, Madison, WI) to generate
pSUR-Luc (Figure 1a).
In order to generate the NIS constructs, the coding
region of NIS was amplified from normal human thyroid
tissue by RT–PCR (nucleotides 348 to 2280, GeneBank
Accession Number, NM_000453), followed by T/A
cloning into the PMD-T18 vector for sequencing. The
sequences of the oligonucleotide primers were as follows:
forward primer, 50-CCCAAGCTTATGGAGGCCGTG
GAGACCGGGGAAC-30, and reverse primer, 50-GCG
TCTAGATCAGAGGTTTGTCTCCTGCTG-30, which
allowed for the introduction of HindIII and XbaI
sites (underlined in the respective sequences). The
luciferase gene of pSUR-Luc was replaced with hNIS by
subcloning into the HindIII and XbaI sites. The survivin
promoter-hNIS-SV40 polyA cassette was then isolated by
digestion with KpnI and SalI and cloned into the
pShuttle-1 vector (Stratagene, Cedar Creek, MD) to
generate pS-SUR-NIS (Figure 1b). Subsequently, homo-
logous recombination was performed using the Adeasier
system (Stratagene) in BJ5183 Escherichia coli to generate
pAd-SUR-NIS. The Ad-SUR-NIS virus was packaged by
transfecting 4mgo fPacI-digested pAd-SUR-NIS DNA
into 293 cells using Lipofectamine2000 (Invitrogen,
Carlsbad, CA) and propagating in 293 cells according to
the standard procedure. After two-step purification on
CsCl gradients, viral stocks were desalted using Pharma-
cia G50 columns (Orsay, France) and frozen at  801Ci n
10mM Tris-HCl (pH 7.5) containing 2.5% glycerol. Viral
titers were calculated by a dilution plaque assay in 293
cells and expressed as PFU per ml. Purification and
plaque assays were performed by SinoGenoMax, Beijing,
China. The recombinant adenovirus, Ad-CMV-NIS,
which uses the CMV promoter to drive NIS expression
(previously described
26), was used as a positive control.
The recombinant adenovirus, Ad-CMV-GFP, which
provided by SinoGenoMax, was used as a negative
control.
Figure 1 Structures of plasmids used in this study. (a) Diagram
represents the structure of the luciferase reporter plasmid.
The survivin promoter ( 222 to 39bp) was cloned upstream of the
luciferase gene using the restriction sites indicated. (b) Diagram
represents the structure of the adenovirus shuttle plasmid pS-SUR-
NIS. The plasmid was constructed by inserting a DNA fragment into
the E1-deleted region using the KpnI/SalI restriction sites. This DNA
fragment contained the survivin promoter, the full length NIS cDNA,
and the Simian Virus 40 polyadenylation signal.
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In order to determine the transcriptional activation
activity of the survivin promoter, we utilized the Dual-
Luciferase reporter assay system (Promega). The plasmid
pRL-TK, which contains the Renilla luciferase gene
under the control of the thymidine kinase promoter,
was used as an internal control. In all, 1 10
6 cells of each
cancer cell line and normal control were plated in six-well
tissue culture plates and 24h later, the cells were
transfected with 4mg of the indicated plasmid DNA and
0.1mg of pRL-TK using Lipofectamine2000 (Invitrogen)
according to the manufacturer’s protocol. At 48h post-
transfection, luciferase activity was determined using the
Reporter Lysis Buffer and Luciferase Assay System
according to the manufacturer’s protocol (Promega).
The dual luciferase ratio was defined as the luciferase
activity of the indicated plasmid divided by the luciferase
activity of pRL-TK. The pSV40-LUC vector (Promega)
that contains Simian Virus 40 (SV40) promoter was used
as a positive control. All experiments were performed in
triplicate.
In vitro
125I and
99mTc pertechnetate uptake
experiments
In all, 1 10
6 cells of each cancer cell line and control
DPF cells were plated in six-well tissue culture plates and
allowed to reach exponential growth for 24h and infected
with Ad-SUR-NIS, Ad-CMV-NIS (positive control) or
Ad-CMV-GFP (negative control) viruses at MOI¼100 in
1ml of medium without serum. After 2h, the media was
changed to complete medium. For each cell line, the
medium used for infection was the same as the culture
medium. Approximately 28–30h after viral infection, cells
were washed once with 1ml of phosphate-buffered saline
(PBS). Iodide uptake was then initiated by adding 1ml
of medium without serum containing 3.7KBq of
125Io r
99mTc pertechnetate per well. Following 30min incuba-
tion with radionuclide, cells were washed twice with
ice-cold PBS and incubated for 20min in 1ml of ice-cold
ethanol. The ethanol was then recovered, and radio-
activity was quantified (c.p.m.) using a g-counter (No. 262
Factory, Xi’an, China). For inhibition experiments, cells
were incubated with both 300mM NaClO4 and
125I for
30min, followed by quantification of
125I uptake as
described above.
In vitro cell killing with
131I and clonogenic assay
Cell killing with
131I was performed according to the
method of Boland et al.
27 described as following: cells
were seeded in 24-well tissue culture plates and divided
into three groups. The first two groups were infected with
the Ad-SUR-NIS adenovirus and the Ad-CMV-GFP
virus, respectively. Thirty hours after infection, cells were
washed once with PBS and incubated with 1ml of serum-
free medium containing 370KBq
131I. The third group
was not infected and was incubated in serum-free
medium. After 7h, cells from all three conditions were
washed twice with PBS, trypsinized, and counted. For
each condition, cells were plated in triplicate in six-well
tissue culture plates (1000cells per well) and incubated for
1 week at 371C. Cells were then washed once with PBS
and stained with crystal violet solution (2gl
–1 crystal
violet, 4% formaldehyde, 20% ethanol). Colonies of 430
cells were counted, and the mean and s.d. of the number
of colonies were determined for each condition. Results
were expressed as the percentage of surviving cells,
defined as the percentage of colonies obtained after
treatment with
131I compared with no intervention,
and are representative of two independent experiments.
Biodistribution of
125I in tumor-bearing mice
Approximately 2 10
7 PC-3 cells were subcutaneously
transplanted into the left or right flank of 6-week-old
Balb/c nude mice and allowed to proliferate until
the tumor reached a diameter of 8–10mm. At this point,
the Ad-SUR-NIS virus or the Ad-CMV-GFP virus
(negative control) was injected into the tumors (both
1 10
9PFU). Radionuclide uptake was assessed 2 days
later by intravenous injection with 370KBq of
125I. At 2,
4, 6 and 12h post-injection, animals were killed, and
selected organs (bone, muscle, heart, lung, liver, spleen,
stomach, intestine, kidney, brain and tumors) were
dissected, weighed and counted for radioactivity.
Scintigraphic imaging of tumor-bearing mice in vivo
Forty-eight hours after intratumoral injection of
1 10
9PFU Ad-SUR-NIS or Ad-CMV-GFP (negative
control), PC-3 tumor-bearing mice were injected with
18.5MBq of
99mTc pertechnetate via the tail vein. After
2h, mice were anesthetized with ketamine and xylazine
and scanned with a g-camera equipped with a pinhole
collimator (Philips Medical Systems, Milpitas, CA).
Effects of NIS expression on
131I therapy in vivo
Accordingly, the PC-3 tumors were induced in Balb/c
nude mice as described above. When the tumors reached
8–10mm in diameter, the mice were given thyroxine
(Sigma-Aldrich, St Louis, MO) at a concentration of
5mgl
–1 in the drinking water for 7 days before treatment.
Two days before treatment, the animals were divided into
two groups of three animals each. One group received an
intratumoral injection of 1 10
9PFU Ad-SUR-NIS. The
other group received an intratumoral injection of
1 10
9PFU Ad-CMV-GFP. Forty-eight hours later,
both groups were given an intraperitoneal dose of
111MBq of
131I (the dose same with Schipper et al.
16 at
their NIS mediate-
131I therapy experiment). The length
and width of the tumors were measured with a caliper at
5-day intervals after treatment. Tumor size was calculated
using the formula: length width
2/2. All mice were
followed for a total of 30 days and then euthanized.
Tumor samples and immunohistochemical staining
In order to detect NIS expression, resected tumors from
nude mice were fixed in 4% paraformaldehyde for 24h.
Samples were immunostained using a standard streptavidin-
biotin labeling protocol. Briefly, after deparaffinization
and antigen retrieval, 5mm tissue sections were incubated
with NIS antibody (mouse monoclonal, 1:100, Chemicon,
Temecula, CA) at 371C for 1h then at 41C overnight.
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anti-mouse immunoglobulin G (1:200, Zymed Labora-
tories, San Francisco, CA) and subsequently incubated
with horseradish peroxidase-labeled streptavidin (1:200,
Zymed Laboratories). The cells were then counterstained
with 3,30-diaminobenzidine for analysis.
Statistical analysis
All data are expressed as mean±s.d. Significance
was determined by the Student’s t-test. Po0.05 was
considered to be statistically significant.
Results
Cancer-specific activation of the survivin promoter
in vitro
To assess whether the activation of the survivin promoter
is cancer specific and to compare the transcriptional
activation activity between the survivin promoter and the
SV40 promoter, we transfected both cancer (PC-3,
HepG2, A375) and normal (DPF) cells with plasmids
containing the luciferase gene under control of either the
survivin promoter (pSUR-Luc) or the SV40 promgfeoter
(pSV40-Luc). Survivin promoter activity was generally
very high in cancer cell lines and very low in normal
cells. The mean dual reporter ratio for cancer and normal
cell lines was 6.76±0.83 and 0.33±0.23, respectively
(Figure 2). However, the activity of the SV40 promoter
was similar in both cancer cell lines and normal cells, with
a mean dual reporter ratio of 2.23±0.08 and 2.23±0.19,
respectively (Figure 2). These data suggest that the
survivin promoter is selectively active in cancer cells
compared with normal cells.
Ad-SUR-NIS is functional in various human cancer
cell lines
An adenovirus that expresses NIS under control of the
survivin promoter (Ad-SUR-NIS) or the CMV promoter
(Ad-CMV-NIS) and a control virus expressing GFP
under control of the CMV promoter (Ad-CMV-GFP)
were generated and used to infect cancer cell lines (PC-3,
HepG2, A375) and non-malignant control cells (DPF). In
order to test the expression of NIS in these cell lines,
functional assays quantifying radioiodine uptake were
performed. Thirty hours after adenovirus infection, iodide
uptake was measured by incubating the cells for 30min
with 3.7KBq of
125I. As shown in Figure 3, all cancer cell
lines infected with Ad-SUR-NIS exhibited significant
iodide uptake, with a mean value of 12092±977c.p.m.
This value represented a 45–56-fold increase over control
Ad-CMV-GFP-infected cells (237±36c.p.m., P¼0.000).
No significant iodide uptake was evident in DPF cells
infected with Ad-SUR-NIS (300±42c.p.m.), consistent
with luciferase reporter assays indicating the specificity of
the survivin promoter for cancer cells (Figure 3). Both
cancer and normal cell lines infected with the general NIS
expression virus Ad-CMV-NIS exhibited significant
iodide uptake. The mean amount of iodide uptake for
all Ad-CMV-NIS-infected cells was 23256±3806c.p.m.,
B85–120 times higher than Ad-CMV-GFP-infected cells,
indicating the efficacy of NIS expression for induction of
radioiodine uptake (Figure 3). In addition to
125I uptake,
cancer cell lines infected with Ad-SUR-NIS also exhibited
selective and increased
99mTc pertechnetate uptake.
The mean amount of
99mTc pertechnetate uptake was
11906±1424c.p.m. for cancer cells (Figure 3). In order to
further demonstrate that uptake of
125I was dependent
Figure 2 In vitro analyses of transgene expression of the survivin
and SV40 promoters by transient transfection. The transcriptional
activity of the survivin and SV40 promoters was measured in various
cancer and normal cells. The data shown are the means±s.d. of at
least three independent experiments.
Figure 3 In vitro radioiodine and
99mTc pertechnetate uptake.
PC-3, HepG2 and A375 cancer cell lines and the control DPF cell line
were infected with Ad-SUR-NIS, Ad-CMV-NIS or Ad-CMV-GFP
viruses and subjected to either
125Io r
99mTc pertechnetate uptake.
Ad-SUR-NIS-infected PC-3, HepG2 and A375 cancer cell lines all
show significant
125I and
99mTc pertechnetate uptake ability
compared with Ad-CMV-GFP-infected controls. No significant uptake
was observed in Ad-SUR-NIS-infected DPF cells. Ad-CMV-NIS
infection resulted in increased
125I uptake in all cell lines. Cotreat-
ment with NaClO4 completely inhibited
125I uptake in Ad-SUR-NIS-
infected cancer cells.
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were treated with the specific NIS inhibitor, sodium
perchlorate during iodide uptake. Figure 3 shows that
sodium perchlorate treatment inhibited iodide accumula-
tion by 92.5±1.2% (P¼0.000).
Ad-SUR-NIS-infected human cancer cells are efficiently
killed by
131I in vitro
In order to demonstrate selective killing of cancer cells
that could be obtained using Ad-SUR-NIS infection in
combination with radioactive iodide treatment,
131I
uptake experiments were performed on Ad-SUR-NIS-
infected PC-3, A375, HepG2 and DPF cells. Ad-CMV-
GFP-infected cells treated with
131I were used as controls.
After
131I treatment, clonogenic assays were performed,
and results were expressed as the percentage of surviving
cells compared with untreated controls. Following ex-
posure to
131I, o10% of Ad-CMV-GFP-infected cells
were killed compared with untreated controls. However,
86±3.5%, 92±3.0% and 89±4.5% of PC-3, A375 and
HepG2 cells, respectively, were killed by
131I following
infection with Ad-SUR-NIS. No significant cell death
was observed in Ad-SUR-NIS-infected DPF cells treated
with
131I, as 91±2.3% of cells were recovered. These
results demonstrate that coupling Ad-SUR-NIS infection
and
131I treatment efficiently and specifically leads to
cancer cell killing in vitro.
125I biodistribution studies in tumor-bearing mice
In order to extend our in vitro results using the Ad-SUR-
NIS virus to an in vivo model, we used nude mice bearing
tumors generated by subcutaneous transplantation of
PC-3 cells as a model. Tumors were injected with either
the Ad-SUR-NIS virus or the control Ad-CMV-GFP
virus, and mice were subjected to
125I treatment 48h later.
Quantitation of the uptake of
125I (% ID per g) in tumors
and various organs was evaluated at 2, 4, 6 and 12h after
125I administration (Table 1). PC-3 tumors infected with
Ad-SUR-NIS accumulated 13.3±2.85% ID per g at 2h,
5.61±1.38% ID per g at 4h, 2.74±0.21% ID per g at 6h
and 0.68±0.05% ID per g at 12h, with a mean effective
half-life of 3.1±0.6h. All other organs accumulated
negligible amounts of isotope (below 2.5% ID per g at
all times) except stomach. The biodistribution data are
summarized in Table 1. Compared with Ad-SUR-NIS-
infected tumors, negative control tumors infected with
Ad-CMV-GFP accumulated 0.66±0.24% ID per g
125Ia t
2h after administration (P¼0.000). At 4, 6 and 12h,
they accumulated 0.42±0.44% ID per g (P¼0.001),
0.34±0.04% ID per g (P¼0.000) and 0.06±0.01% ID
per g (P¼0.014), respectively. These data indicate that
infection of tumors with the Ad-SUR-NIS virus leads to
selective uptake of
125I in vivo.
Visualization of Ad-SUR-NIS-infected tumors by
99mTc pertechnetate scintigraphy
In order to test whether Ad-SUR-NIS-infected tumors
could be visualized in vivo, scintigraphy was performed on
tumor-bearing mice using
99mTc pertechnetate, allowing
imaging with a pinhole collimator.
99mTc pertechnetate
(18.5MBq) was injected intraperitoneally, and images
were taken after 2h (Figure 4). As expected, tissues
naturally expressing NIS (stomach and thyroid) or
involved in iodide elimination (bladder) were visualized.
The Ad-SUR-NIS-infected tumor was clearly visible, with
intensity comparable to that of the thyroid or the bladder.
However, the Ad-CMV-GFP-infected PC-3 tumor was
not visible.
Decreased tumor growth induced by Ad-SUR-NIS
infection in combination with
131I treatment
In vitro studies suggested that Ad-SUR-NIS infection
combined with radioiodine treatment can inhibit growth
of cancer cells. In order to extend these results to an
in vivo model, tumors were generated in Balb/c nude mice
and infected with either Ad-SUR-NIS or Ad-CMV-GFP.
After 48h, mice were treated with
131I as described in the
Materials and methods. As shown in Figure 5, tumors in
Table 1 Biodistribution of
125I pertechnetate in mice with Ad-SUR-
NIS-injected PC-3 xenografts (% ID per g tissue; mean and s.d. after
intravenous injection)
Organ 2h 4h 6h 12h
Stomach 14.7±0.72 9.42±1.59 4.44±0.86 0.54±0.12
Tumor 13.3±2.85 5.61±1.38 2.74±0.21 0.68±0.05
Heart 1.25±0.23 0.31±0.27 0.29±0.10 0.14±0.01
Liver 1.21±0.26 0.45±0.25 0.46±0.17 0.20±0.04
Spleen 1.00±0.31 0.53±0.26 0.56±0.28 0.12±0.01
Lung 1.48±0.34 0.66±0.25 0.53±0.26 0.15±0.02
Kidney 2.10±0.51 0.89±0.19 0.66±0.27 0.16±0.03
Intestinal 1.78±0.69 0.37±0.43 0.53±0.29 0.17±0.03
Muscle 0.60±0.16 0.40±0.09 0.37±0.01 0.07±0.02
Bone 1.44±0.33 0.84±0.09 0.48±0.08 0.28±0.01
Brain 0.16±0.04 0.04±0.11 0.07±0.01 0.05±0.03
Figure 4
99mTc pertechnetate scintigraphic images of PC-3
xenografts infected with either Ad-CMV-GFP or Ad-SUR-NIS. Mice
harboring PC-3 xenograft tumors infected with either Ad-CMV-GFP
(a) or Ad-SUR-NIS (b) were imaged with a pinhole collimator 2h after
injection of 18.5MBq
99mTc pertechnetate. (a) The Ad-CMV-GFP-
infected tumor is not visible using
99mTc pertechnetate imaging.
(b) The Ad-SUR-NIS-infected tumor is clearly visible, with an
intensity comparable to that of the thyroid or the bladder.
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131I and Ad-CMV-GFP continued
to grow until the end of the experiment. In contrast,
tumors in animals that received injections of both Ad-
SUR-NIS intratumorally and
131I intraperitoneally began
to show a slight reduction in growth on day 10 and day
15, and from day 20 to day 30, tumor volumes in this
group were statistically different from Ad-CMV-GFP-
infected controls. The volume reduction rates at days 20,
25 and 30 were 32.9±11.3% (P¼0.029), 46.2±4.4%
(P¼0.001) and 51.4±15.9% (P¼0.012), respectively.
These results suggest that expression of NIS in combina-
tion with
131I treatment may prove to be a possible
strategy for reduction of tumor growth in vivo.
Membrane expression of NIS in tumors injected
with Ad-SUR-NIS
For in vivo experiments, expression of the NIS protein in
the tumor was characterized by immunohistochemical
staining. Tumors injected with Ad-SUR-NIS were
specifically labeled with anti-NIS antibodies. Labeling
was clearly confined to cell membranes, indicating that
expression of NIS driven by the Ad-SUR-NIS virus
leads to correct localization of the NIS protein in vivo.
Representative tumor sections are shown in Figure 6.
Discussion
Consistent with the role of NIS in the success of
radioiodine therapy for thyroid cancer, targeted expres-
sion of NIS provides the possibility of NIS-targeted
radionuclide therapy for treatment of non-thyroidal
tumors.
27–29 In contrast to other potential therapeutic
genes, therapeutic use of NIS has several advantages. The
potential function of NIS as a diagnostic gene allows
non-invasive radioiodine imaging to confirm and localize
functional NIS expression before proceeding to the
application of a therapeutic
131I dose. NIS gene therapy
may also be more effective due to a substantial bystander
effect caused by treatment with the b-emitter
131I, which
has a path length of up to 2–4mm, and can cause the
death of NIS-expressing cells as well as neighboring non-
transfected cells.
30
The ultimate goal of cancer therapy is to maximize
cancer cell-specific cytotoxicity and minimize toxic side
effects in non-malignant cells. Gene therapy using tissue-
specific promoters provides a means of selectively
targeting therapeutic genes to malignant cells.
31 Several
cancer-specific targeting promoters are available for
targeting of individual cancers, including the prostate
specific antigen promoter (prostate cancer), the albumin
enhancer and promoter (hepatocellular cancer), the CEA
promoter (medullary thyroid cancer, colorectal cancer),
the MUC-1 promoter (breast cancer, pancreatic cancer)
and the chromogranin A promoter (neuroendocrine
tumors). These promoters are cancer-type specific, but
are limited in scope.
The expression of survivin is noted in common human
cancers but not in normal adult tissues. As the increased
survivin activity is controlled transcriptionally, it has been
suggested that the survivin promoter might control the
transgene expression in a cancer-specific manner.
32,33
Figure 5 Therapeutic effects of Ad-SUR-NIS infection in combina-
tion with
131I treatment in PC-3 xenografts. Tumor size was assayed
after
131I treatment in nude mice bearing tumors infected with either
Ad-SUR-NIS or Ad-CMV-GFP. Growth of Ad-SUR-NIS-infected PC-
3 tumors was significantly retarded (*
,**
,***Po0.05) at days 20, 25
and 30 after injection of 111MBq
131I.
Figure 6 Representative immunostaining of NIS in tumors from nude mice. Note the distinct cell membrane staining of NIS in the PC-3 tumor
infected with Ad-SUR-NIS (a). In contrast, the non-infected PC-3 tumor is negative for NIS immunoreactivity (b). Original magnification for each
panel was  400.
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of survivin promoter were extremely low in the major
mouse organs, and therefore, it may prove to be a good
candidate for transcriptional targeting of cancer gene
therapy in a wide variety of tumors.
34 So in this study, we
used the survivin promoter as a candidate promoter to
test the feasibility of using a multicancer-specific promo-
ter to extend the scope of a gene-based therapy. The
survivin promoter was used to target hNIS expression and
induce radionuclide accumulation in three representative
cancers: prostate cancer, hepatocarcinoma and melano-
ma, all of them have relatively high incidence and
mortality in China.
Our data indicated that the survivin promoter could
drive luciferase expression specifically in cancer cells. The
survivin promoter was 2–3 times more active than the
SV40 promoter, consistent with the previous reports.
32,34
This observation suggests that the survivin promoter
could induce high transgene expression in cancer cells.
In in vitro functional studies, the survivin promoter
was shown to be capable of driving functional NIS
expression in three different cancer cell lines. Expression
of NIS via the Ad-SUR-NIS virus increased perchlorate-
sensitive iodide uptake to 50-fold over that of Ad-CMV-
GFP-infected cancer cells. Furthermore, no significant
iodide uptake was observed in Ad-SUR-NIS-infected
DPF cells, indicating that the virus was selective for
cancer cells. Scintigraphy and biodistribution studies
confirmed that specific accumulation of radionuclide
also occurred in Ad-SUR-NIS-infected PC-3 tumors
in vivo.
For effective treatment using radioisotopes, it is
important that the tumor receives a high radiation dose.
The dose is determined by the level of uptake, which in
this case was controlled by the level of NIS expression and
the available amount of iodide, and the effective half-life
of the isotope in the tumor, which is a product of the
physical half-life (8.021 days for
131I) and the biological
half-life of the isotope. The biological half-life depends on
several factors, including the rates of internalization and
externalization and whether the isotope is organified in
the cell. A controversy exists regarding the feasibility of
NIS gene therapy for extrathyroidal tumors that cannot
organify trapped iodide, which is thought to be a crucial
prerequisite for effective radioiodine therapy. However,
data from several groups working in non-organifying
extrathyroidal tumor models, including prostate cancer,
hepatocarcinoma and myeloma, clearly demonstrate
that a significant therapeutic effect of
131I can be achieved
after NIS gene transfer in the absence of organifica-
tion.
5,9,35 In these studies, either a long effective half-life
or sufficient residual radioactivity led to effects in tumor
cells.
We investigated the possibility of combining Ad-SUR-
NIS infection with
131I radionuclide therapy for treatment
of cancer. An in vitro clonogenic study showed that
coupling Ad-SUR-NIS and
131I treatments efficiently and
specifically killed multiple types of cancer cells. Similar
treatments in an in vivo tumor model showed that
combining Ad-SUR-NIS infection with
131I treatment
retarded the tumor growth compared to controls. This
result is not as significant as the studies discussed above,
due to the mean effective half-life of
131I in Ad-SUR-NIS-
infected PC-3 tumors is less than them, so some additional
considerations should be used to improve the therapeutic
efficacy of the combinatorial treatment.
One approach involves the cotransfection of thyroid
peroxidase and NIS.
36 Another practical approach
involves the use of more powerful therapeutic radio-
nuclides such as
211At or
188Re.
6,8,37 These radionuclides
have similar chemical properties to iodine and more
favorable physical properties, including a higher linear
energy transfer and shorter physical half-life. Therefore,
treatments using these radionuclides should result in an
increased radiation dose and, thus, enhanced efficacy. A
recent study by Willhauck et al.
8 demonstrated the
therapeutic efficacy of
211At in LNCaP cells stably
expressing NIS under the control of the prostate specific
antigen promoter (NP-1) in vivo.
211At was found to have
an effective half-life of 4.6h, and treatment caused a
significant reduction in tumor volume of up to 82%.
8 This
and other similar studies provide information that can
help to develop optimized therapeutic regimens for use
with the Ad-SUR-NIS system. Regarding the use of the
adenoviral transport system, a regime that includes
multiple injections of adenovirus/radioiodine is likely to
enhance reduction in tumor volume. Use of a condition-
ally replicating adenovirus as a platform for delivery of
NIS may represent another potential alternative. This
type of virus would be able to replicate and spread within
the tumor, thus increasing the rate of tumor-cell clearance
due to radioiodide uptake.
An important potential complication of this therapeutic
regimen must also be considered. Special care must be
taken to protect the thyroid gland from damage.
Generally, we utilize thyroid hormone pretreatment,
which suppresses thyroidal
131I uptake, which is known
to be selectively regulated by the thyroid-stimulating
hormone. However, if thyroidal radioiodine uptake did
cause damage to the thyroid gland, effects on patients
could easily and inexpensively be managed by routine
thyroid hormone replacement therapy.
28 Due to the local
accumulation of
131I, the stomach, salivary glands,
bladder and colon lumen also receive the high radiation
doses. Although no significantly increased risk of stomach
and bladder was observed in thyroid cancer patients
treated with radioactive iodine, the increased risks of
colorectal and salivary gland cancers were found with
higher cumulative amount of
131I, which should be
minimized by a simple routine of having patients drink
large quantities of fluids and lemon juice, and by the use
of laxatives.
38–40
In conclusion, the therapeutic effect of combining
survivin promoter-driven expression of NIS and
131I
treatment has been demonstrated in three different cancer
cell types in vitro. Furthermore, survivin promoter-driven
expression of NIS also induced tumor-specific iodide
accumulation and a reduction in tumor growth in an
in vivo PC-3 xenotransplant model in nude mice. Future
studies will focus on enhancing the therapeutic effects
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Cancer Gene Therapyof this treatment through the use of more powerful
therapeutic radionuclides, such as
211At or
188Re,
and through revision of the adenoviral delivery system.
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